Citation Impact
Citing Papers
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
2008 Standout
Role of LBPA and Alix in Multivesicular Liposome Formation and Endosome Organization
2004 StandoutScienceNobel
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
The endothelial glycocalyx: composition, functions, and visualization
2007 Standout
Recent insights into antiphospholipid antibody-mediated thrombosis
1999
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
The Emerging Role of Recombinant-Activated Factor VII in Neurocritical Care
2004
Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome
2017
Myocardial Infarction and Other Arterial Occlusions in Hemophilia A Patients
2006
Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma
2001
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies
2003
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
2005 Standout
Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events
2002
Intracranial haemorrhage in haemophilia A and B
2007
Early Coagulopathy Predicts Mortality in Trauma
2003 Standout
Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
2008 Standout
The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition
2016 Standout
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Insight into nanoparticle cellular uptake and intracellular targeting
2014
Down syndrome
2020 Standout
Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004–2008)
2010
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Factor V Leiden: A Clinical Review
2001
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral Hemorrhage
2004
Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage
2006 Standout
Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor
2002
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery
1998
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
Interaction of Anti-Phospholipid Antibodies With Late Endosomes of Human Endothelial Cells
2000
Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses
2002
Annexins: From Structure to Function
2002 Standout
Ultra-Early Hemostatic Therapy for Intracerebral Hemorrhage
2003
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
Guidelines for the management of hemophilia
2012 Standout
Works of M Schmidt being referenced
Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia a patients with inhibitors
1994
Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with Inhibitors
1998
Christianson Syndrome Protein NHE6 Modulates TrkB Endosomal Signaling Required for Neuronal Circuit Development
2013
Evidence against heterozygous coagulation factor V 1691 G?A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction
1995
A First Mutation in the Human Tissue Factor Pathway Inhibitor Gene Encoding [P151L]TFPI
1998
Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant.
1995
A First Mutation in the Human Tissue Factor Pathway Inhibitor Gene Encoding [P151L]TFPI
1998